D. Kramer et al., Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats, METABOLISM, 50(11), 2001, pp. 1294-1300
Thiazolidinediones (TZDs), a class of antidiabetic agents, are specific ago
nists of peroxisome proliferator activator receptor (PPAR gamma). However,
their mechanisms of action, and the in vivo target tissues that mediate ins
ulin sensitization are not well understood. The aim of this study was to in
vestigate the role of glucose transporters (GLUT-1 and GLUT-4) in the TZD i
nsulin-sensitizer action. The effects of rosiglitazone treatment were studi
ed using Zucker (fa/fa) rats after 7 days of oral dosing (3.6 mg/kg/d). Ros
iglitazone lowered (approximate to 80%) basal plasma insulin levels in obes
e rats and substantially corrected (approximate to 50%) insulin resistance
based upon results from hyperinsulinemic euglycemic clamp studies. GLUT-4 p
rotein levels were reduced (approximate to 75%) in adipose tissue of obese
rats and treatment with rosiglitazone normalized them. Interestingly, GLUT-
1 protein content was increased in adipose tissue (approximate to 150%) and
skeletal muscle (approximate to 50%) of obese rats and treatment with rosi
glitazone increased it even more by 5.5-fold in fat and by 2.5-fold in musc
le. Consistent with these results, basal (GLUT-1-mediated) transport rate o
f 3-O-methyl-D-glucose into isolated epitrochlearis muscle was elevated in
response to rosiglitazone. Incubation of fully differentiated 3T3-L1 adipoc
ytes with the drug for 7 days increased the levels of GLUT-1 protein, but d
id not affect GLUT-4 levels. In conclusion, rosiglitazone may improve insul
in resistance in vivo by normalizing GLUT-4 protein content in adipose tiss
ue and increasing GLUT-1 in skeletal muscle and fat. While the drug has a d
irect effect on GLUT-1 protein expression in vitro without a direct effect
on GLUT-4 suggests that direct and indirect effects of rosiglitazone on glu
cose transporters may have an important role in improving insulin resistanc
e in vivo. Copyright (C) 2001 by WB. Saunders Company.